Clinical Trial

Consolidation Therapy With Cladribine in Relapsing Multiple Sclerosis Patients

Study acronym: OCR_CLAD
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
To investigate the impact on IgG and IgM concentration, infection risk and effectiveness of switching from anti-CD20 to cladribine compared to continued anti-CD20 treatment over 2 years in relapsing MS patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-25.
Status change: Recruiting → Active, Not Recruiting 2026-03-11
Trial Details
NCT Number NCT06854094
Lead Sponsor Ente Ospedaliero Cantonale, Bellinzona
Collaborators: 3B Biotech Research
Conditions Multiple Sclerosis
Enrollment 70 participants
Start Date 2024-10-03
Primary Completion 2026-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-12